HC Wainwright Reiterates Buy Rating for BiomX (NYSEAMERICAN:PHGE)

BiomX (NYSEAMERICAN:PHGE)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $2.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 423.42% from the company’s current price. HC Wainwright also issued estimates for BiomX’s Q1 2024 earnings at ($0.07) EPS, Q2 2024 earnings at ($0.08) EPS, Q3 2024 earnings at ($0.08) EPS and Q4 2024 earnings at ($0.06) EPS.

BiomX Price Performance

Shares of NYSEAMERICAN:PHGE opened at $0.38 on Wednesday. The firm has a market capitalization of $17.57 million, a PE ratio of -0.59 and a beta of 1.36. BiomX has a one year low of $0.19 and a one year high of $0.86. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.98 and a current ratio of 1.98.

Hedge Funds Weigh In On BiomX

An institutional investor recently bought a new position in BiomX stock. 8VC GP I LLC purchased a new stake in shares of BiomX Inc. (NYSEAMERICAN:PHGE) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 1,086,191 shares of the company’s stock, valued at approximately $304,000. BiomX accounts for approximately 0.3% of 8VC GP I LLC’s holdings, making the stock its 3rd largest holding. 8VC GP I LLC owned about 2.36% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).